Propofol has been detected in human breath after being used as an intravenous anaesthetic, and this could provide a noninvasive method for monitoring propofol anaesthesia.
Introduction
Propofol (2,6-diisopropylphenol) is widely used for induction and maintenance in clinical anaesthesia, or for sedation in the intensive care unit as an intravenous anaesthetic. 1 Propofol total intravenous anaesthesia (TIVA) has been shown to have some advantages over traditional volatile anaesthesia, 2 although the presence of propofol infusion syndrome 3 and the absence of a clinically useful method for measuring propofol anaesthesia levels limit the application of propofol to general anaesthesia. Thus, developing a clinically effective method for monitoring propofol anaesthesia depth, such as monitoring of Y Gong, E Li, G Xu et al. Propofol concentrations in human breath by HS-SPME-GC-MS inhalation anaesthetics with minimum alveolar concentration (MAC), is important.
Propofol has a phenolic chemical structure with a distinct smell, a molecular weight of 178.27 g/mol, low water solubility and is somewhat volatile. In some studies propofol has been detected in breath and attempts have been made to measure propofol concentrations in breath as a means of monitoring blood propofol levels. 4 -8 Although headspace solid-phase microextraction gas chromatography-mass spectrometry (HS-SPME-GC-MS) has previously been used to detect propofol in human breath, 8 the present study used a different method to prepare the calibration gas samples. The aim of the present study was, therefore, to investigate levels of propofol in human breath and plasma in subjects under propofol TIVA, by applying a different HS-SPME-GC-MS pre-conditioning method.
Patients and methods

REAGENTS AND CHEMICALS
Propofol pure reagent was provided by Sigma-Aldrich ® (St Louis, MO, USA; assay ≥ 97%). Propofol 1% (w/v) was purchased from AstraZeneca (Caponago, Italy). SPME 85 µm polyacrylate (PA)-fibres were obtained from Supelco ® (a division of Sigma-Aldrich ® ). Tedlar ® bags (1.0 l) manufactured from polyvinyl fluoride were provided by Dalian Delin Gas Packing Co. Ltd (Dalian, China).
PREPARATION OF CALIBRATION STANDARDS
A total of 1 µl propofol pure reagent was injected into a 1366 ml sealed spherical bottle at 250°C. The propofol reagent was immediately and completely vaporized. After the temperature in the spherical bottle had slowly fallen from 250°C to 25°C ± 2°C, a stock of propofol gas was prepared by transferred 5 ml of gas containing propofol from the spherical bottle into a Tedlar ® bag using a 50 ml gas-tight syringe (Agilent Inc., Santa Clara, CA, USA). Calibration gas samples containing 3.6, 7.3, 14.6, 36.5, 73.0 and 109.5 ng/l of propofol were then generated by dilution of the stock propofol gas sample in Tedlar ® bags filled with nitrogen.
Stock plasma solutions were prepared by mixing 5 ml plasma, prepared from blood freshly drawn from healthy volunteers, with 1 µl propofol 1% (w/v). From this, calibration plasma solutions containing 0.2, 1.0, 2.5, 5.0 and 10.0 mg/l of propofol were then prepared. Each analytical plasma sample was diluted (1:100) with saline before the sample was analysed.
PATIENTS AND ANAESTHESIA
The study protocol was approved by the Health Research Ethics Board of The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. Patients with American Society of Anesthesiologists physical status I or II who were about to undergo elective abdominal surgery and who agreed to participate in the study were included. All patients included in the study provided written informed consent.
Anaesthesia was induced with 0.1 mg/kg midazolam, 0.1 mg/kg vecuronium and 2 µg/kg fentanyl administered intravenously. After tracheal intubation, the lungs were ventilated with a tidal volume of 8 ml/kg, the respiratory rate was 12 breaths/min and the inspiration:expiration ratio was 1:2 with 3 l/min fresh gas. After intubation, a breath sample and an arterial blood sample were collected from each patient. Immediately after sample collection, propofol was continuously infused at a rate of 4 mg/kg per h for 60 min, then 6 mg/kg per h for the next 60 min, and 9 mg/kg per h for the final 60 min. At the end of each infusion period, 
SAMPLING OF BREATH AND BLOOD
A teflon T-piece with a septum was fixed in the expiratory limb of an anaesthetic circuit. In order to eliminate residual propofol, the anaesthetic circuit was washed by high-flow fresh air for 1 h before anaesthesia was performed. A 20 ml alveolar breath gas sample was withdrawn via the T-piece using a gas-tight silanized glass syringe and transferred into a 20 ml evacuated silanized sealed glass vial with a chlorinated butyl rubber stopper for SPME.
A 50 µl arterial blood sample was taken at each time point and added into a heparin anticoagulant tube before centrifugation at 3000 g. Then 10 µl of the supernatant plasma sample was diluted (1:100) with saline. Following this, 10 µl of the diluted plasma sample was transferred into a 20 ml evacuated silanized sealed glass vial with a chlorinated butyl rubber stopper for SPME.
PRE-CONCENTRATION OF GAS AND PLASMA SAMPLES
An SPME 85 µm PA-fibre was used for breath and plasma headspace pre-concentration.
A 20 ml gas sample was injected into a 20 ml evacuated silanized sealed glass vial with a chlorinated butyl rubber stopper using a gas-tight silanized glass syringe. The SPME fibre was pierced through the septum of the headspace vial at 60°C for 25 min. The fibre was then withdrawn and transferred into the injection port of the gas chromatograph. The temperature of the injection port was set at 260°C and the desorption time was 7 min. Each measurement was repeated five times.
A 10 µl diluted plasma sample was added into a 20 ml evacuated silanized sealed glass vial with a chlorinated butyl rubber stopper. The SPME fibre was pierced through the septum of the headspace vial at 38°C for 25 min. The fibre was then withdrawn and transferred into the injection port of the GC. The temperature of the injection port was set at 260°C and the desorption time was 7 min. Each measurement was repeated five times.
GC-MS ANALYSIS
A gas chromatography-mass spectrometer (QP2010; Shimadzu Corp., Kyoto, Japan) equipped with an Rtx ® -5 MS fused-silica capillary column (30 m length, 0.32 mm internal diameter, 0.25 µm film thickness) (Restek, Bellefonte, PA, USA) was used for propofol analysis. The carrier gas was helium with a 2.23 ml/min flow rate. The injector inlet (splitless) temperature was 260°C. The GC program was started at 70°C for 1 min and then raised to 115°C for 2 min at a rate of 3°C/min, before being raised to 250°C for 3 min at a rate of 30°C/min. The splitless time was 1 min. Electron ionization was 70 eV. The scan mode was selected-ion monitoring in order to enhance the sensitivity at mass-to-charge ratios (m/z) of 163 and 178. The total ion concentration was calculated as the sum of the peak areas at m/z 163 and m/z 178.
STATISTICAL ANALYSIS
Linear regression analysis was performed to assess the correlation between the propofol concentration in the breath and plasma samples. The data were analysed using SPSS ® version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value < 0.05 was considered to be statistically significant.
Results
The calibration curves were fitted by plotting the peak areas versus the propofol concentrations. The linear ranges were 3.6 -
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109.5 ng/l and 0.2 -10.0 mg/l for propofol in breath (r 2 = 0.9634) and in plasma (r 2 = 0.9941), respectively. Detection limits were 1.8 ng/l for propofol in breath and 0.05 mg/l for propofol in plasma, and the lower limits of quantitation were 3.6 ng/l and 0.2 mg/l, respectively.
Intraday precision and recovery percentages were 4.3 -6.7% and 98 -108%, respectively, for propofol detection in breath at concentrations of 7.3, 36.5 and 109.5 ng/l ( Table 1 ). The interday precision was 3.2 -8.3% in breath. Intraday precision and recovery percentages for propofol detection in plasma at concentrations of 0.2, 2.5 and 10.0 mg/l were 3.8 -6.1% and 90.1 -125.1%, respectively ( Table 1 ). The interday precision for propofol detection in plasma was 2.8 -7.4%.
The measured concentrations of propofol in breath from the three patients included in the study ranged from 4.3 to 33.5 ng/l and the propofol plasma concentrations ranged from 3.2 to 6.8 mg/l. The correlation between breath and arterial plasma propofol concentrations was indicated by regression analysis, where r 2 = 0.8290 for the three individual patients (Fig. 1) . Chromatograms for exhaled breath and plasma samples from a typical patient are shown in Fig. 2 .
Discussion
Some pilot studies have shown that it is possible to detect propofol in breath samples from patients who have received intravenously administered propofol anaesthesia. 4 -8 The analytical methods used have included proton transfer reaction MS (PTR-MS), 4,5 ion-molecule reaction MS (IMR-MS), 6 Tenax ® TA GC-MS 7 and HS-SPME-GC-MS. 8 A different pre-conditioning method was used in the present study on account of physicochemical properties of propofol.
Propofol has a boiling point of 256°C and a vapour pressure of 0.142 mmHg at 20°C. Thus, in the present study, 1 µl of pure reagent propofol could be completely vaporized into propofol gas at 250°C in a 1366 ml sealed bottle. Additionally, the temperature of the vaporized propofol was cooled slowly from 250°C to 25°C to ensure that the propofol gas would not condense while cooling and return to liquid form. Both the propofol gas and the expired gas in the present study were treated as an ideal gas. The volume of 1 mol of an ideal gas at 25°C
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Tedlar ® bag to create a calibration curve and the linear range of the SPME method was sufficient to allow propofol to be measured in human breath under propofol TIVA. A reliable correlation between propofol concentrations in breath and arterial plasma was also demonstrated.
The propofol concentrations in expired breath in the present study were lower in comparison with results reported by Takita et al. 5 and Miekisch et al., 8 whereas the propofol concentrations in plasma were similar to those found by these researchers. Takita et al. 5 used PTR-MS to monitor expired gases. The PTR-MS method relies on empirical algorithms in which a reliable kvalue (reaction rate constant for proton transfer) for propofol has not been reported in the literature, and these investigators used preliminary calibration under these operating conditions to obtain the F value (overall conversion factor including k and t [reaction time]). They estimated that the uncertainty of the propofol concentration was approximately ±30% during the preliminary calibration, and this may have resulted in the measured concentration being higher than the real-time concentration. In the study reported by Miekisch et al., 8 gas calibration was carried out by transferring 10 ml of propofol-free expired air and 5 µl of methanolic propofol solution containing an adequate amount of the drug and 0.925 nmol/l thymol, into a 20 ml evacuated sealed glass vial before adsorption by SPME for 5 min at 40°C for GC-MS analysis. In contrast, Takita et al., 5 heated the sample tube to 70°C in order to prevent condensate forming in the tube. It is uncertain whether the propofol solution was completely vaporized and this may have result in a measured concentration that was different from the real-time concentration reported by Miekisch et al. 8 Like PTR-MS, IMR-MS 6 is another direct MS method. It depends on single-point calibrations for quantitative analysis and cannot report actual concentrations but, rather, detects mass signals (counts/s).
Additionally, the problem of residual volatile propofol in the long sampling line was not resolved for these direct MS techniques, which also indicates that the expired propofol concentrations may not reflect the real-time concentration. Numerous contaminants are present in the clinical environment which would interfere with propofol analysis by direct MS. Tenax ® TA GC-MS 7 is a good method for overcoming these problems, but the procedure is complicated. The present study used HS-SPME as a substitute for Tenax ® TA. The HS-SPME method simplifies sample extraction, purification and concentration to a single step. 9 The HS-SPME-GC-MS method is also more accurate and reliable than direct MS, although direct MS techniques can be used to measure exhaled gases continuously. HS-SPME-GC-MS may also be useful as a scientific analytical method for the study of propofol pharmacokinetics and pharmacodynamics. 10 The optimal technique for monitoring exhaled propofol has, however, yet to be established and research on the measurement of propofol in expired gas is ongoing.
